Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2025-09-18 M&A Activity
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT REGARDING THE CONNECTED TRANSACTION IN RELATION TO THE ACQUISITIONS OF (1) ASSETS OF SANROAD SHANGHAI AND (2) ENTIRE EQUITY INTEREST IN XIANWEI
M&A Activity Classification · 97% confidence The document is a detailed Hong Kong stock exchange announcement providing supplemental information on a connected transaction concerning the acquisition of assets of Sanroad Shanghai and the entire equity interest in Xianwei. It outlines transaction background, vendor ownership, and valuation methodologies. This is a corporate M&A-related announcement rather than an earnings release, board change, or report publication notice. Therefore, it best fits the M&A Activity category (TAR).
2025-09-18 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 96% confidence The document is a Next Day Disclosure Return (FF305) under Hong Kong listing rules detailing changes in issued shares, including the issue and allotment of new shares on September 10, 2025. It is a regulatory announcement about a share issuance event and capital change, not a full financial report, earnings release, or buyback. Therefore, it fits the definition of a Share Issue/Capital Change.
2025-09-10 English
COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update Classification · 92% confidence The document is an announcement by Simcere Pharmaceutical Group Limited detailing the completion of a share placing (existing shares) and a top‐up subscription of new shares under the company’s general mandate. It includes the number of shares placed and subscribed, the price per share, use of proceeds, and post‐transaction shareholding structure. This is a corporate financing/fundraising event, fitting the Capital/Financing Update category.
2025-09-10 English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0609 (CDH17 ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 75% confidence The document is a Hong Kong exchange announcement regarding the Company’s clinical trial approval from China’s National Medical Products Administration. It does not present financial results, management changes, dividend notices, or other specified categories. It is a general corporate update and does not neatly fit any of the specific filing types, so it falls under the fallback category “Regulatory Filings” (RNS).
2025-09-08 English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF DEUNOXAVIR MARBOXIL GRANULES WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 80% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited on the acceptance of a new drug application (NDA) by the National Medical Products Administration. It is not a financial report (annual, interim, earnings release), not a management change, not a capital financing update, nor any other specified corporate filing type. It is a general business update/press release regarding regulatory progress and thus falls into the fallback category “Regulatory Filings” (Code: RNS).
2025-09-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Share Issue/Capital Change Classification · 93% confidence The document is an FF301 form, a monthly return filed with the Hong Kong Exchange covering movements in the issuer’s share capital, treasury shares, share options, and RSU scheme under Listing Chapter 19B for the month ended 31 August 2025. It details share issuance movements (which in this case are nil) and disclosures of grants under its RSU scheme. This is clearly a regulatory filing about share issuance and capital changes, matching the definition of Share Issue/Capital Change (SHA).
2025-09-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.